In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1311-1318

  Brož, Daniela Kenzelmann ^a   Attardi, Laura D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL STRESS; CELL TYPE; GENE MUTATION; GENETIC ENGINEERING; HUMAN; KNOCKOUT MOUSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

ANIMALS; CELL AGING; CELL CYCLE; CELL DIVISION; DNA DAMAGE; GENES, P53; GENETIC ENGINEERING; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASMS; POINT MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955354374     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp331     Document Type: Review

References (64)

1. Soussi,T. (2007) p53 alterations in human cancer: more questions than answers. Oncogene, 26, 2145-2156.
2. Varley,J.M. (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat., 21, 313-320.
3. Clarke,A.R. et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849-852.
4. Donehower,L.A. et al. (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal in-stability. Genes Dev., 9, 882-895.
5. Donehower,L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
6. Jacks,T. et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4, 1-7.
7. Vousden,K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
8. Vousden,K.H. et al. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413-431.
9. Attardi,L.D. et al. (1999) The role of p53 in tumour suppression: lessons from mouse models. Cell Mol. Life Sci., 55, 48-63.
10. Tsukada,T. et al. (1993) Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene, 8, 3313-3322.
11. Ihrie,R.A. et al. (2004) Perp-etrating p53-dependent apoptosis. Cell Cycle, 3, 267-269.
12. Kuperwasser,C. et al. (2000) Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol., 157, 2151-2159.
13. Jonkers,J. et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet., 29, 418-425.
14. Artandi,S.E. et al. (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature, 406, 641-645.
15. Cadwell,C. et al. (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene, 277, 15-30.
16. Lavigueur,A. et al. (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell Biol., 9, 3982-3991.
17. Harvey,M. et al. (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet., 9, 305-311.
18. Lang,G.A. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell, 119, 861-872.
19. Olive,K.P. et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell, 119, 847-860.
20. Stiewe,T. (2007) The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer, 7, 165-168.
21. Song,H. et al. (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol., 9, 573-580.
22. Terzian,T. et al. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev., 22, 1337-1344.
23. Murray-Zmijewski,F. et al. (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol., 9, 702-712.
24. Toledo,F. et al. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer, 6, 909-923.
25. Armata,H.L. et al. (2007) The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res., 67, 11696-11703.
26. Chao,C. et al. (2003) Cell type-and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem., 278, 41028-41033.
27. Sluss,H.K. et al. (2004) Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell Biol., 24, 976-984.
28. MacPherson,D. et al. (2004) Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J., 23, 3689-3699.
29. Chao,C. et al. (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J., 25, 2615-2622.
30. Luo,J.L. et al. (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene, 20, 320-328.
31. Feng,L. et al. (2006) Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle, 5, 2812-2819.
32. Bruins,W. et al. (2004) Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol. Cell Biol., 24, 8884-8894.
33. Lin,T. et al. (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol., 7, 165-171.
34. Feng,L. et al. (2005) Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell Biol., 25, 5389-5395.
35. Krummel,K.A. et al. (2005) The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA, 102, 10188-10193.
36. Chao,C. et al. (2006) Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell Biol., 26, 6859-6869.
37. Tang,Y. et al. (2008) Acetylation is indispensable for p53 activation. Cell, 133, 612-626.
38. Green,D.R. et al. (2009) Cytoplasmic functions of the tumour suppressor p53. Nature, 458, 1127-1130.
39. Riley,T. et al. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402-412.
40. Lin,J. et al. (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev., 8, 1235-1246.
41. Johnson,T.M. et al. (2005) The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat. Genet., 37, 145-152.
42. Hammond,E.M. et al. (2006) Genome-wide analysis of p53 under hypoxic conditions. Mol. Cell Biol., 26, 3492-3504.
43. Johnson,T.M. et al. (2008) Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc. Natl. Acad. Sci. USA, 105, 1215-1220.
44. Toledo,F. et al. (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell, 9, 273-285.
45. Toledo,F. et al. (2007) Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol. Cell Biol., 27, 1425-1432.
46. Symonds,H. et al. (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78, 703-711.
47. Yin,C. et al. (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature, 385, 637-640.
48. Schmitt,C.A. et al. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell, 1, 289-298.
49. Liu,G. et al. (2004) Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet., 36, 63-68.
50. Barboza,J.A. et al. (2006) p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl. Acad. Sci. USA, 103, 19842-19847.
51. Cosme-Blanco,W. et al. (2007) Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep., 8, 497-503.
52. Halazonetis,T.D. et al. (2008) An oncogene-induced DNA damage model for cancer development. Science, 319, 1352-1355.
53. Schmitt,C.A. et al. (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev., 13, 2670-2677.
54. Christophorou,M.A. et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat. Genet., 37, 718-726.
55. Christophorou,M.A. et al. (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature, 443, 214-217.
56. Hinkal,G. et al. (2009) Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One, 4, e6654.
57. Efeyan,A. et al. (2006) Tumour biology: policing of oncogene activity by p53. Nature, 443, 159.
58. Martins,C.P. et al. (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell, 127, 1323-1334.
59. Xue,W. et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656-660.
60. Ventura,A. et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature, 445, 661-665.
61. Maier,B. et al. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev., 18, 306-319.
62. Tyner,S.D. et al. (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature, 415, 45-53.
63. Matheu,A. et al. (2007) Delayed ageing through damage protection by the Arf/p53 pathway. Nature, 448, 375-379.
64. Mendrysa,S.M. et al. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev., 20, 16-21.